Gilead’s Move on GS-1179 and ABI-6250: A Catalyst-Backed Long Idea
Advancements on GS-1179 and ABI-6250 tied to Gilead’s collaboration with Assembly Biosciences raise the odds of meaningful future revenue optionality. Strong free cash flow, a $171.7B market cap and yield support a conservative long trade: entry $138.35, target $155.00, stop $128.00, horizon 180 trading days.